Permixon (Permixon)

Permikson has complex effects on the pathogenesis and symptoms of benign prostatic hyperplasia, effects due to complementary constituent ingredients of the plant extract.Permixon has antiandrogenic, anti-inflammatory, anti-edematous and antiproliferative effects, selectively manifested at the level of the prostate gland. In this case, the drug does not affect the level of sex hormones in the blood, does not cause impairment of sexual functions, libido, potency and does not change the serum PSA (prostate-specific antigen) level. The local anti-androgenic effect of Permixon is associated with inhibition of the enzyme 5-alpha-reductase 1 and 11 types, which is responsible for the conversion of testosterone in the prostate into its active form, dihydrotestosterone, and a decrease in binding of the latter to specific receptors. Reducing the formation of dihydrotestosterone results in a decrease in further growth in prostate volume.

Local anti-inflammatory effect is caused by the effect of lipidosterol extract of serenoid creeping on the main mediators of cellular inflammation - inhibits the activity of phospholipase A2, cyclooxygenase and lipoxygenase. Permixon during the first weeks of treatment reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, eliminates the compression of the neck of the bladder and urinary canal, like alpha blockers improves urodynamics.The local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and the acceleration of apoptosis of prostate cells, which is reflected in inhibition of growth and a subsequent decrease in the volume of the prostate gland. These properties of the drug contribute, on the one hand, to a reduction in the pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, painful sensations and a feeling of tension during urination, incomplete emptying of the bladder), an increase in the volume and strength of urination. On the other hand, Permixon contributes to inhibition of further growth and volume of the prostate gland.